Warburg Pincus Eyes Maneesh Pharma Unit
US private equity firm Warburg Pincus is reportedly in negotiations to acquire a segment of Maneesh Pharmaceuticals focused on non-tuberculosis drugs. The deal is estimated to be valued between ₹1,600 to ₹1,800 crore (approximately $192 million to $215 million). This acquisition aligns with Warburg Pincus’s strategy to expand its pharmaceutical presence in India.
The potential acquisition reflects ongoing interest from private equity firms in the Indian pharmaceutical sector, driven by the growth prospects and potential for consolidation. Maneesh Pharmaceuticals, while not as widely recognized as some of its larger peers, has a notable presence in specific therapeutic areas, making it an attractive target for strategic investors like Warburg Pincus.
If the deal materializes, it would provide Warburg Pincus with a platform to further build its portfolio of pharmaceutical assets in India, leveraging Maneesh Pharma’s existing infrastructure and market access. The transaction is anticipated to be finalized in the coming months, pending regulatory approvals and final due diligence.
About the Author
